SSRIs during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies

First published: 03/05/2017 Last updated: 02/07/2024





## Administrative details

EU PAS number		
EUPAS18909		
Study ID		
23798		
DARWIN EU® study		
No		
Study countries		
United Kingdom		

**Study description** 

Perform a systematic review of observational studies assessing the risk of autism spectrum disorder and attention deficit hyperactivity disorder associated with maternal selective serotonin re-uptake inhibitor (SSRI) exposure during pregnancy.

#### **Study status**

Finalised

### Research institutions and networks

### **Institutions**

### European Medicines Agency (EMA)

First published: 01/02/2024

**Last updated:** 01/02/2024

Institution

### Contact details

### **Study institution contact**

Morales Daniel Daniel. Morales@ema.europa.eu

Study contact

Daniel.Morales@ema.europa.eu

### **Primary lead investigator**

Morales Daniel

#### **Primary lead investigator**

## Study timelines

#### Date when funding contract was signed

Planned: 04/07/2016

Actual: 04/07/2016

### Study start date

Planned: 18/07/2016 Actual: 18/07/2016

#### Data analysis start date

Planned: 25/07/2016 Actual: 01/08/2016

#### **Date of final study report**

Planned: 19/06/2017 Actual: 15/01/2018

# Sources of funding

EMA

# Study protocol

EUPAS18909.protocol.pdf (63.19 KB)

# Regulatory

Was the study required b	y a regulatory body?
--------------------------	----------------------

Yes

### Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Methodological aspects

# Study type

# Study type list

#### **Study topic:**

Disease /health condition

Human medicinal product

#### Study type:

Non-interventional study

#### Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

#### **Data collection methods:**

Secondary use of data

### Main study objective:

To undertake a systematic review identifying observational studies evaluating risk of autism spectrum disorder and attention deficit hyperactivity disorder

following maternal exposure to selective serotonin re-uptake inhibitors during pregnancy. To assess confounding adjustment within studies and the different effect estimates for different reference groups reported.

# Study Design

#### Non-interventional study design

Systematic review and meta-analysis

# Study drug and medical condition

#### **Anatomical Therapeutic Chemical (ATC) code**

(N06AB) Selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors

#### Medical condition to be studied

Autism spectrum disorder

Attention deficit hyperactivity disorder

## Population studied

#### Short description of the study population

Women during pre-pregnancy or pregnancy with or without serotonin re-uptake inhibitor (SSRI) exposure.

#### Age groups

• Infants and toddlers (28 days - 23 months)

• Children (2 to < 12 years)

#### **Estimated number of subjects**

10000

## Study design details

#### **Outcomes**

ASD and ADHD

#### **Data analysis plan**

To describe the type of studies, their characteristics and the variables used for confounding adjustment by them. To describe the types of comparator groups used to compare risk from SSRI exposure with a focus on:maternal exposure during pregnancy compared to all unexposed women, maternal exposure during the pre-pregancy period compared to all unexposed women, maternal exposure during pregnancy compared to all unexposed women with an affective disorder, paternal exposure during pregnancy, and sibling designs. To explore the effect of meta-analysis for different exposures using generic inverse variance method of analysis in Review Manager.

### **Documents**

#### Study results

EUPAS18909.summary.results.pdf (122.67 KB)

#### Study publications

Morales DR, Slattery J, Evans S, Kurz X. Antidepressant use during pregnancy an...

## Data management

ENICADD CAA

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

#### **Data sources (types)**

Published literature

## Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

### **Check stability**

Unknown

### **Check logical consistency**

Unknown

### Data characterisation

### **Data characterisation conducted**

Unknown